To access all features of this site, you must enable Javascript. Here are the instructions for enabling Javascript in your web browser.
To carry out their activities, Research Teams of the Frédéric Joliot Institute for Life Sciences have developed high-profile technological platforms in many areas : biomedical imaging, structural biology, metabolomics, High-Throughput screening, level 3 microbiological safety laboratory...
All the news of the Institute of life sciences Frédéric Joliot
A team from SIMoS and SCBM, in collaboration with researchers from I2BC, has shown that autophagic degradation is at work when mammalian cells are poisoned by ricin. Stimulating this process could provide additional protection against this deadly toxin.
En substituant des segments d’hélice alpha par des segments d’oligo-urées dans un peptide inhibiteur d’ASF1, lui conférant ainsi une résistance accrue aux protéases, des chercheurs de l’I2BC en collaboration avec l’IECB explorent les modes de liaison de ces chimères peptide-urée à leur cible.
A collaborative study by NeuroSpin researchers, using anatomical MRI data and a dimensional approach in 850 subjects from the Healthy Brain Network cohort, shows how the social skills of these children and adolescents are linked to the structure of their cerebellum
Le 07 septembre, l'équipe MIND organisait son kick-off meeting, symbolisant la volonté commune de sestutell es, CEA et Inria, de consolider et de créer des synergies en intelligence artificielle et machine learning pour les neurosciences.
Researchers at BioMaps (SHFJ) and SPI (DMTS) have studied the pharmacokinetics of a novel immuno-radioligand targeting the endothelin A receptor (ETA), overexpressed in many cancers, particularly glioblastoma. The immunoPET imaging approach used in this study in a preclinical model confirms the theranostic potential of this antibody.
Des chercheurs du SCBM et de l’Iramis publient une étude preuve-de-concept d’un composé radiosensible qui pourrait servir à « libérer » in vivo des médicaments anti-tumoraux, et ainsi de combiner les effets d’une radiothérapie et d’une chimiothérapie.
Top page
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.